JP7626910B2 - Rafキナーゼの阻害剤 - Google Patents

Rafキナーゼの阻害剤 Download PDF

Info

Publication number
JP7626910B2
JP7626910B2 JP2022523904A JP2022523904A JP7626910B2 JP 7626910 B2 JP7626910 B2 JP 7626910B2 JP 2022523904 A JP2022523904 A JP 2022523904A JP 2022523904 A JP2022523904 A JP 2022523904A JP 7626910 B2 JP7626910 B2 JP 7626910B2
Authority
JP
Japan
Prior art keywords
carboxamide
trifluoroethyl
pyrrolidine
methylphenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554169A5 (cg-RX-API-DMAC7.html
JP2022554169A (ja
Inventor
ダブリュー. カルドー,ステファン
カノウニ,トウフィケ
ティホナス,ジョン
エー. マーフィー,エリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of JP2022554169A publication Critical patent/JP2022554169A/ja
Publication of JP2022554169A5 publication Critical patent/JP2022554169A5/ja
Application granted granted Critical
Publication of JP7626910B2 publication Critical patent/JP7626910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022523904A 2019-10-24 2020-10-23 Rafキナーゼの阻害剤 Active JP7626910B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962925596P 2019-10-24 2019-10-24
US62/925,596 2019-10-24
US202063044898P 2020-06-26 2020-06-26
US63/044,898 2020-06-26
PCT/US2020/057132 WO2021081375A1 (en) 2019-10-24 2020-10-23 Inhibitors of raf kinases

Publications (3)

Publication Number Publication Date
JP2022554169A JP2022554169A (ja) 2022-12-28
JP2022554169A5 JP2022554169A5 (cg-RX-API-DMAC7.html) 2023-10-30
JP7626910B2 true JP7626910B2 (ja) 2025-02-05

Family

ID=75619376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523904A Active JP7626910B2 (ja) 2019-10-24 2020-10-23 Rafキナーゼの阻害剤

Country Status (16)

Country Link
US (3) US11098031B1 (cg-RX-API-DMAC7.html)
EP (1) EP4048259A4 (cg-RX-API-DMAC7.html)
JP (1) JP7626910B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220104702A (cg-RX-API-DMAC7.html)
CN (1) CN114845711B (cg-RX-API-DMAC7.html)
AU (1) AU2020371727B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158530A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000998A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022006712A2 (cg-RX-API-DMAC7.html)
IL (1) IL292424B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004937A (cg-RX-API-DMAC7.html)
PH (1) PH12022550976A1 (cg-RX-API-DMAC7.html)
TW (1) TWI899110B (cg-RX-API-DMAC7.html)
WO (1) WO2021081375A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204284B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024517431A (ja) * 2021-04-23 2024-04-22 キネート バイオファーマ インク. (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
AU2020371727B2 (en) * 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
US20230046018A1 (en) * 2019-12-06 2023-02-16 Medshine Discovery Inc. Biaryl compound as pan-raf kinase inhibitor
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2022060996A1 (en) * 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
TW202308645A (zh) * 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療
US20240327343A1 (en) * 2021-07-19 2024-10-03 Kinnate Biopharma Inc. Preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride
CN115974851A (zh) * 2021-10-14 2023-04-18 华领医药技术(上海)有限公司 2-氧代-3-氮杂双环[3.1.0]己烷衍生物
WO2023070053A1 (en) * 2021-10-21 2023-04-27 Kinnate Biopharma Inc. Inhibitors of raf kinases
AU2022405115A1 (en) * 2021-12-09 2024-07-11 Deciphera Pharmaceuticals, Llc Raf kinase inhibitors and methods of use thereof
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
TW202342055A (zh) 2022-02-03 2023-11-01 美商奇奈特生物製藥公司 Raf激酶抑制劑
US20250171462A1 (en) * 2022-03-02 2025-05-29 Nico Therapeutics, Inc. Compounds, compositions, and methods
US20260100247A1 (en) * 2022-09-30 2026-04-09 Foundation Medicine, Inc. Systems and methods for processing clinico-genomic data

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
JP2016517417A (ja) 2013-03-14 2016-06-16 ノバルティス アーゲー キナーゼ阻害剤としてのビアリールアミド化合物
JP2017526720A (ja) 2014-09-12 2017-09-14 ノバルティス アーゲー キナーゼ阻害剤としての化合物および組成物
JP2017527585A (ja) 2014-09-12 2017-09-21 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
JP2017528475A (ja) 2014-09-12 2017-09-28 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
JP2022525885A (ja) 2019-03-22 2022-05-20 キネート バイオファーマ インク. Rafキナーゼの阻害剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
EP2252612B1 (en) 2008-02-22 2012-03-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
KR101652229B1 (ko) 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
BR112018075371A2 (pt) 2016-06-10 2019-03-19 Novartis Ag usos terapêuticos de um inibidor de c-raf
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2020168172A1 (en) 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
JP2016517417A (ja) 2013-03-14 2016-06-16 ノバルティス アーゲー キナーゼ阻害剤としてのビアリールアミド化合物
JP2017526720A (ja) 2014-09-12 2017-09-14 ノバルティス アーゲー キナーゼ阻害剤としての化合物および組成物
JP2017527585A (ja) 2014-09-12 2017-09-21 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
JP2017528475A (ja) 2014-09-12 2017-09-28 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
JP2022525885A (ja) 2019-03-22 2022-05-20 キネート バイオファーマ インク. Rafキナーゼの阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of medicinal chemistry,2019年05月06日,63(5),2013-2027

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024517431A (ja) * 2021-04-23 2024-04-22 キネート バイオファーマ インク. (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態

Also Published As

Publication number Publication date
MX2022004937A (es) 2022-07-27
US11098031B1 (en) 2021-08-24
EP4048259A1 (en) 2022-08-31
EP4048259A4 (en) 2023-08-02
AU2020371727B2 (en) 2026-01-22
US20260055084A1 (en) 2026-02-26
TW202128680A (zh) 2021-08-01
CA3158530A1 (en) 2021-04-29
BR112022007612A2 (pt) 2022-09-20
PH12022550976A1 (en) 2023-09-25
IL292424B2 (en) 2026-06-01
NZ788005A (en) 2024-10-25
IL292424B1 (en) 2026-02-01
CN114845711A (zh) 2022-08-02
KR20220104702A (ko) 2022-07-26
TWI899110B (zh) 2025-10-01
IL292424A (en) 2022-06-01
CO2022006712A2 (es) 2022-05-31
JP2022554169A (ja) 2022-12-28
CL2022000998A1 (es) 2023-02-10
ZA202204284B (en) 2024-09-25
US12312336B2 (en) 2025-05-27
WO2021081375A1 (en) 2021-04-29
AU2020371727A1 (en) 2022-05-26
US20210300904A1 (en) 2021-09-30
CN114845711B (zh) 2024-10-01

Similar Documents

Publication Publication Date Title
AU2020371727B2 (en) Inhibitors of RAF kinases
WO2020198058A1 (en) Inhibitors of raf kinases
JP2021529740A (ja) サイクリン依存性キナーゼの阻害剤
WO2017181177A1 (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
JP2018513119A (ja) ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
WO2022060996A1 (en) Inhibitors of raf kinases
CA3226796A1 (en) Novel parp7 inhibitor and use thereof
JP2025508323A (ja) Cdk4/6キナーゼの阻害薬
US20240166635A1 (en) Aminoheteroaryl kinase inhibitors
JP7349570B2 (ja) M4作動薬としての2-アザスピロ[3.4]オクタン誘導体
ES2968733T3 (es) Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CN117677616A (zh) 制备血红蛋白调节剂的方法
JP2024544794A (ja) (s)-2-(2-メチルアゼチジン-1-イル)ピリミジン誘導体およびそれを含む医薬組成物
EP4211118A1 (en) Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator
HK40077347A (zh) Raf激酶的抑制剂
HK40077347B (en) Inhibitors of raf kinases
HK40063842A (en) Inhibitors of raf kinases
TW202527956A (zh) M4陽性變構調節劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241113

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241209

R150 Certificate of patent or registration of utility model

Ref document number: 7626910

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150